Back to news

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire•20/11/2026•07:01 ET
2

Key Highlights

  • ➤39,146 inducement RSUs granted to five new Precision BioSciences employees
  • ➤RSUs vest in substantially equal annual installments over three years
  • ➤Awards approved November 16, 2026, under Nasdaq Rule 5635(c)(4)

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of an aggregate total of 39,146 restricted stock units (“RSUs”), granted among five employees in connection with their commencement of employment. Each award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in